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Heart development in mammals is followed by a postnatal decline in cell proliferation and cell renewal from stem cell populations.
A better understanding of the developmental changes in cardiac microenvironments occurring during heart maturation will be
informative regarding the loss of adult regenerative potential. We reevaluate the adult heart’s mitotic potential and the reported
adult cardiac stem cell populations, as these are two topics of ongoing debate. The heart’s early capacity for cell proliferation
driven by progenitors and reciprocal signalling is demonstrated throughout development. The mature heart architecture and
environment may be more restrictive on niches that can host progenitor cells. The engraftment issues observed in cardiac stem
cell therapy trials using exogenous stem cells may indicate a lack of supporting stem cell niches, while tissue injury adds to a
hostile microenvironment for transplanted cells. Engraftment may be improved by preconditioning the cultured stem cells and
modulating the microenvironment to host these cells. These prospective areas of further research would beneﬁt from a better
understanding of cardiac progenitor interactions with their microenvironment throughout development and may lead to
enhanced cardiac niche support for stem cell therapy engraftment.
1. Cell Turnover in the Heart: A Loss of
Mitotic Potential
The heart has been a focus since the earliest medical research,
yet some of the basic knowledge of heart cell biology has
remained uncertain for almost a century. Before the concept
of stem cells was known, a question was how the heart could
maintain its essential function as a hard working organ
throughout a human lifespan. A comparative lack of dividing
cells had been observed in the adult heart by early histological
detection of mitotic cells. Analyses of DNA synthesis in
rodent heart tissues over subsequent decades indicated that
the rate of DNA synthesis was extremely low in normal heart
muscle and slightly increased in injured adult heart, whereas
it was much higher during development and until adoles-
cence [1]. Cardiomyocytes were found to stop dividing in
the postnatal period when a switch occurs from hyperplasia
to hypertrophy during terminal diﬀerentiation, and further
heart growth is achieved through cell enlargement [2]. In
rodents, this was detected by an increase in binucleated cells
produced by cardiomyocytes synthesising DNA without
completing cell division [3]. Human cardiomyocytes, which
are less frequently arrested in a binucleated state (26–60%)
than rodent cells (up to 90%), instead show increasing mono-
nuclear polyploidy in the ﬁrst decades of life [2–4]. Binucle-
ated cells were speculated to provide metabolic beneﬁt
through increased transcription of mRNA [5], at the expense
of cell renewal.
For many decades, it was taught that the heart was essen-
tially restricted in cell number after birth, unable to regener-
ate after injury, and adapting to increased workload through
cell enlargement. Studies using labelling and other tech-
niques had nevertheless suggested some cardiomyocyte
renewal; this was proposed to balance a rate of cell loss
through apoptosis and called for a reevaluation of the termi-
nally diﬀerentiated state of ventricular myocytes in the adult
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mammalian heart [6, 7]. The highest reported heart cell
renewal rates raised the prospect of several tissue replace-
ments per lifetime, as well as new cardiomyocyte generation
after injury [8]. This led to a widening range of experimental
data [9] and a useful revision of the dogma, but it was not
easily understood in view of the clinical prevalence of heart
failure, a chronic condition highlighting the lack of cardiac
regenerative capacities. However, it was noted that organ
damage including ﬁbrosis is irreversible even in organs with
high cell turnover, suggesting these are separate issues [6].
The ﬁeld was more reconciled with studies using a method
based on 14C isotope decay measurement in humans. This
estimated the rate of cardiomyocyte DNA synthesis in adult-
hood as less than 1% per year, following a gradual decrease
from childhood [4, 10]. It was calculated that less than half
of cardiomyocytes may be replaced during a normal lifespan
[10]. Interestingly, in adult heart, the cell renewal rates of
endothelial cells (>15% per year) and mesenchymal cells
(<4% per year) were much higher than those of cardiomyo-
cytes [4]. The overall arrest in cell division of cardiomyocytes
after birth in mammals is not as yet explained but is associ-
ated with downregulation of positive cell cycle regulators, as
well as centrosome disassembly [3, 11]. The potential for cell
division is thought more likely to be retained in mononucle-
ated cells or in smaller cells [5]. In lower vertebrates, how-
ever, the mitotic apparatus seems preserved [11]. Zebraﬁsh
displays a higher regenerative potential of organs including
the heart, where the response to injury was found to reacti-
vate cardiomyocyte proliferation of a subset of cells undergo-
ing limited dediﬀerentiation [12–14]. In mammals, a low rate
of cardiovascular replacement was conﬁrmed and traced
back to existing dividing cardiomyocytes [15].
Following revision and debate, it was proposed that cell
turnover in the mammalian heart muscle occurs at a very
low rate [16], which may contribute to its structural mainte-
nance. It is normally insuﬃcient to heal the heart after injury
and in disease, but conditions or drugs may be identiﬁed that
can stimulate the cells retaining mitotic potential [10]. Such
cells remain abundant in lower vertebrates, but in mammals,
these cells are predicated on rare mitotic cardiomyocytes or
on the existence of progenitor and stem cells in an adult car-
diac niche. The key to understanding the fate of proliferating
cells in the adult heart may be found during its development,
when active cell division is supported in dynamic cardiac
microenvironments.
2. Heart Development: Assembling Progenitor
Cells from Different Sources
Heart development is marked by growth transitions produc-
ing a cardiac tube and then causing its looping and partition-
ing until it reaches its ﬁnal full-sized chambered heart
structure (Figure 1). The process starts soon after embryo
gastrulation at embryonic day 6.5 (E6.5) of mouse develop-
ment, when the mesoderm is formed between the ectoderm
and the endoderm germ layer during ingression through
the primitive streak. The earliest cardiac progenitors are
bilateral groups of cells that originate in the anterior meso-
derm and migrate and extend across the ventral midline into
a cardiac crescent at E7.5, which is referred as the ﬁrst or pri-
mary heart ﬁeld [17]. They are joined by a second group of
progenitor cells from the underlying pharyngeal mesoderm
forming the second heart ﬁeld [18]. By E8, cardiac crescent
cells migrate to the midline, merging the abutments of this
arch to form a primitive heart tube. This is composed of beat-
ing cardiomyocytes lined with endothelial endocardial cells,
separated by an extracellular matrix (ECM) named cardiac
jelly. Endocardial cell commitment is thought to occur prior
to their migration into the heart ﬁeld [19]. The slightly later
diﬀerentiating cells from the second heart ﬁeld add to the
ends of the heart tube to become the arterial and venous poles
[18]. The initial heartbeat is found at the inﬂow region of this
heart tube, but subsequent pacemaker cells are thought to
arise from the right lateral plate mesoderm [20, 21]. At this
stage, the heart tube already functions as a valveless pump
with a compound mechanism [22]. Looping and bulging of
this rapidly growing tube creates the left ventricle from pri-
mary heart ﬁeld cells, and most of the right ventricle and
the outﬂow tract from secondary heart ﬁeld cells. By E10.5,
the venous poles have pushed up anteriorly and dorsally to
form the future atria composed of cells from both ﬁelds.
Development is completed with the septation of the cham-
bers and valve formation from endocardial cushions by
E15.5 [23]. During this time, cells of neural crest origin
migrate from the dorsal neural tube and complete the separa-
tion of the outﬂow tracts. Progenitor cells from the extracar-
diac mesoderm, termed the third heart ﬁeld, migrate to an
anterior location on the heart where they form a transient
structure, the proepicardium. Proepicardial cells generate
the epicardium by gradually covering the heart towards its
apex [24, 25]. Lineage tracing showed that proepicardial cells
(a) (b) (c) (d) (e) (f)
Figure 1: Summary of mouse heart development. (a) E3.5 preimplantation blastocyst stage showing pluripotent inner cell mass (ICM); (b)
E6.5-gastrulating embryo showing mesoderm formation (arrows); (c) at E7.5, myocardial progenitor cells migrate to form the cardiac
crescent; (d) at E8, the cardiac crescent fuses at the midline to form the early cardiac tube; (e) at E8.5, the cardiac tube forms a loop; (f) at
E12.5–E15.5: the chambers undergo septation.
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are also the source of coronary vasculature cells [19]. The
niche created at the interface between epicardium, myocar-
dium, and nascent vasculature recruits migrating fetal mac-
rophages of yolk sac origin [26]. Cardiac ﬁbroblasts are also
thought to originate from cells migrating out of the proepi-
cardial organ or from epithelial to mesenchymal transition
(EMT) during valve formation [27]. Importantly, this sug-
gests that the role of the early mesoderm progenitors in
organogenesis is taken over by a proepicardial niche in later
cardiac development [24].
3. Developmental Signalling Environments:
Inducing Cell Proliferation
and Differentiation
Signalling from the surrounding microenvironment directs
the transcription regulation of the developmental pro-
gramme of the heart, necessary for diﬀerentiation (Figure 2)
as well as proliferation. Speciﬁcation of the cardiac progenitors
is induced by endoderm-produced bone morphogenic protein
(BMP) and suppressed by neural Wnt signals [28]. Gata4 and
NKX2.5 are the central transcription factors common to car-
diac progenitors, whereas Tbx5 and ISL1 are speciﬁc to cardiac
progenitors of the ﬁrst and second heart ﬁelds, respectively
[29, 30]. These progenitors diﬀerentiate primarily into cardio-
myocytes forming heart muscle but also endocardial cells
forming the endothelial lining, as well as endothelial cells
and vascular smooth muscle cells forming the blood vessels.
Cardiomyocytes can further specialise into pacemaker cells
generating the electrical impulses and the Purkinje cells con-
ducting these [20, 21]. Other progenitors lead to the cardiac
ﬁbroblasts in connective tissues, the epicardial cells forming
the outer layer of the heart, pericytes, and resident immune
cells [23]. Signalling between these cells further determines
morphogenesis in the developing heart [31]. For instance,
during development, embryonic cardiac ﬁbroblasts promote
cardiomyocyte proliferation through ECM/β1 integrin signal-
ling. In addition, endocardial release of neuregulin 1 (NRG-1)
regulates cardiomyocyte diﬀerentiation and proliferation
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Figure 2: Summary of some of the cell diﬀerentiation stages with characteristic transcription factor markers (red) during embryonic
development from zygote to cardiac and endothelial tissue.
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necessary for trabecular growth within the ventricles, along
with NOTCH1, VEGFR-2, and FGF signalling [32]. In turn,
the myocardium releases ANG-1 required for diﬀerentiation
and proliferation of the endocardium [33]. Myocardium also
releases TGF-β, BMP, Wnt, and Notch signals regulating
the EMT of cells in the endocardium during valve develop-
ment [31]. Conduction cells diﬀerentiate from a subset of
contractile cardiomyocytes in response to paracrine signals
including endothelin-1 [34]. Epicardial retinoic acid (RA)
activates FGF signalling important for proliferation in com-
pact myocardium and for inducing downstream Wnt signal-
ling promoting EMT for growth of the coronary vasculature.
In turn, signalling from the myocardium regulates epicardial
development [31, 35].
The dependence on signalling pathways in heart develop-
ment [28] shows that these provide proliferation and diﬀer-
entiation cues from the earliest speciﬁcation of progenitors
in the cardiac crescent to the ﬁnal heart chamber formation.
Niche interactions occur through soluble paracrine signals or
physical contacts through integrins and cadherins, which are
coupled with cytoplasmic receptors that transduce these sig-
nals to the nucleus, where they regulate transcription [36].
Additionally, heart morphogenesis is directed by mechanor-
egulation from the nascent circulation, pressure load, and
myocardium contractility [37, 38]. These signals are trans-
duced via various cell sensors that respond to ﬂow, pressure,
stretching, and rhythmicity [39]. The resulting diﬀerential
gene expression patterns are supported and stably propa-
gated through new cell lineages by epigenetic mechanisms
[40]. Heart developmental gene regulation was shown to be
determined by chromatin remodelling, histone acetylation
and methylation, and DNA methylation [41–45]. The heart
has not only provided an early example of the contributions
of epigenetic modiﬁers of gene expression to organogenesis;
interestingly, it showed a partial reactivation of developmen-
tal histone deacetylases in adult disease [46–49]. In addition,
the chromatin-remodelling complex BRG1 was reported to
reactivate in response to cardiac stress [50, 51]. However,
outside a developmental environment, adult cardiomyocyte
reactivation results in cell growth rather than proliferation
[49]. Similarly, the fate of progenitors seems to be aﬀected
by the transition from developing tissues to the mature con-
ﬁguration of the adult heart.
4. The Adult Cardiac Microenvironment:
Confining Space and Signals for Function
Adult mammalian heart tissue has a specialised architecture
that serves its essential contractile function (Figure 3). Cardi-
omyocytes are characterised by the ability of a subset of sino-
atrial and atrioventricular nodal or Purkinje cells to generate
action potentials and beat spontaneously; the automaticity
of these cardiac pacemaker cells involves hyperpolarisation-
activated and cyclic nucleotide-gated (HCN) channels
[52, 53]. Contraction of cardiac muscle is produced by
myoﬁbrils formed by chains of sarcomeres, in which actin
ﬁlaments interact with myosin ﬁlaments, the structural integ-
rity of which is essential [54]. The left ventricular wall
consists of lamellar units of myocardial cells in a helical
arrangement, which gradually shifts in angle from a left-
handed myocyte spiral in the outer zone, through a circum-
ferential zone in the middle part, to a right-handed spiral in
the inner zone of the wall [55]. In sections taken across the
dense wall, these cardiomyocytes also show connections in
radially twisted transmural sheets, which are less tightly
coupled towards the inside wall of the left ventriculum [56].
A three-dimensional network of connective tissue sur-
rounds and connects these myocardial sheets, lamellae, and
cells, through an extracellular collagen matrix termed the
perimysial weave [56]. This interstitial collagen is produced
by cardiac ﬁbroblasts, which are present in similar numbers
as the cardiomyocytes in the adult heart [57, 58]. Cell-
sorting measurements have shown that the proportion of
ﬁbroblasts is species speciﬁc, and that it is low in embryonic
Cardiomyocytes
Smooth muscle cells
Endothelial cells 
Endothelium
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Simple squamous
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Figure 3: Adult heart architecture with left ventricle wall cross section showing the myocardium organisation with the endocardium lining
and epicardium outer layers. Cell types drawn are mature cardiomyocytes, cardiac ﬁbroblasts in their collagen matrix, endothelial cells of the
endocardium and capillaries, Purkinje ﬁbres, and epithelial and connective tissue cells of the epicardium.
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heart but increases during late foetal and neonatal growth
[59], reﬂecting its longer period of proliferation. Neverthe-
less, the ﬁbroblasts also stop dividing after heart matura-
tion, although this is thought to be due to a quiescent
state from which a subset can reenter the cell cycle [59].
Cardiac ﬁbroblast markers such as discoidin domain recep-
tor 2 (DDR2) and vimentin can distinguish these cells from
cardiomyocytes expressing α-myosin heavy chain (α-MHC),
cardiac troponin T (cTnT), HCN4, and NKX2.5 [60]. How-
ever, some cell markers are not found present in the whole
population of cardiac ﬁbroblasts or are not speciﬁc to this
cell type alone [61]. This unusual ﬁbroblast cell type can
conduct electrical signals via connexins through gap-
junctional coupling with each other as well as with cardio-
myocytes [61, 62], showing it contributes structurally as well
as functionally to heart function.
Other abundant occupants of the heart are the endothe-
lial cells, which can be endocardial (the lining of the heart)
or vascular (coronary arterial, venous, capillary, and lym-
phatic cells) [19]. Recent methodology suggests that endothe-
lial cells are more numerous than the other main cell types,
but they only make up a small volume [58]. A high density
of capillaries in the myocardial interstitial space ensures the
supply of oxygen and nutrients to other cells, as well as com-
munication via paracrine factors released by endothelial cells
including nitric oxide, reactive oxygen species, endothelin-1,
natriuretic peptides, and cytokines [35]. The epicardium
forms the outer layer of the adult heart composed of connec-
tive tissue, adipose tissue, and surrounding mesothelium, a
single layer of epithelial cells in contact with the pericardial
ﬂuid [25]. In addition to coronary vessels and nerves, the
subepicardium niche environment remains host to macro-
phages and several other cell types identiﬁed by electron
microscopy, including immature cardiomyocytes [26, 63].
Several of these cell types have mesenchymal stem cell
(MSC) characteristics or other markers of potential progeni-
tor cells in the heart [64].
Overall, the dense construction of mature myocardium
embedded in a ﬁbroblast matrix with the endothelial capil-
lary network, with signalling integral to cardiac physiology
and its contractile function, leaves few potential sites for
adult cardiac stem cell-supporting niches. The loose connec-
tive subepicardial tissue surrounding the heart remains a
separate niche environment featuring mixed cell types
including potential progenitors. These are known to diﬀeren-
tiate into several cell types, including cardiomyocytes [65].
Interstitial spaces around blood vessels in the myocardium
are further high nutrient environments for interactions
between resident and itinerant cells. Microscopic evidence
for adult stem cell niches was reported at such locations in
the atria and apex [6, 66].
5. The Cardiac Microenvironment in Disease:
Stress Signals and Responses
Cardiac ﬁbroblasts can proliferate in response to patholog-
ical stimuli [57, 59]. The source of these activated cardiac
ﬁbroblasts was initially thought to include resident cells
and circulating progenitors [57], rapidly inﬁltrating a site
of injury. More recent lineage tracing studies suggest that
the response involves mainly resident cardiac ﬁbroblasts,
although contributions from perivascular cells and epicar-
dial cells are possible [61, 67, 68]. Abnormal ECM changes
during injury cause activated cardiac ﬁbroblasts to undergo
a TGF-β-induced and mechanoregulated diﬀerentiation to
myoﬁbroblasts, which express αSMA, ﬁbronectins, stress
ﬁbres, and contractile activity. This initial response to heart
injury can eventually lead to cardiac remodelling and
chronic heart failure [69]. Further unexpected roles of myo-
ﬁbroblasts have been suggested in regulating apoptotic
engulfment [70].
Cell division of preexisting cardiomyocytes is low but is
increased adjacent to areas of myocardial injury, whereas it
is reduced by aerobic respiration-mediated oxidative DNA
damage [15, 71]. Stress signalling in the myocardium further-
more switches on genes encoding fetal isoforms of proteins
[72]. Normally quiescent epicardial cells also proliferate to
form epicardium-derived cells (EPDCs) that diﬀerentiate
into mesenchymal cells; whether these can subsequently
populate the adult myocardium is under debate [27]. An
important extrinsic factor altering the cardiac niche is
the inﬂammatory response occurring after myocardial
infarction. In the ischemic phase, the infarcted tissue suf-
fers necrosis and release of cytokines triggered by tumor
necrosis factor TNF-α. Reperfusion brings on a further
damaging inﬂammation response with recruitment of neu-
trophils, monocytes, and further cytokines, which trigger
ﬁbroblast proliferation and neovascularization [73]. The
gross changes following cardiac injury and inﬂammation
lead to an increase in myoﬁbroblasts that will initially
repair, then remodel the heart with a more rigid ECM
[74]. This maladaptive response overshadows the reactiva-
tion of other progenitors or proliferating cells in this overall
nonregenerative environment.
6. Resident Cardiac Progenitors: Uncovering
Residual Heart Developmental Capacity
The existence of progenitor populations in the adult heart
has been the focus of many studies [75]. The criteria in
the search for cardiac progenitor cells are that they should
reside in the heart as a self-renewing pool of multipotent cells
able to diﬀerentiate into the main cardiac lineages. Table 1
summarises reported examples of cardiac resident side popu-
lation cells, ISL1+ progenitors, c-Kit+ cells, Sca1+ cells, epi-
cardial progenitors, and mesenchymal cells. Here, we will
focus on the cells that have been investigated in more detail.
6.1. Cardiac c-Kit+ Cells. Multipotent, clonogenic, and self-
renewing c-Kit+ cells isolated from bone marrow were ﬁrst
claimed to be able to substantially regenerate injured myo-
cardial tissue [82]. Resident c-Kit+ cells in the heart were also
reported to have this regenerative capacity [83, 84], suggest-
ing a role in cardiac repair. In the heart, these cells were
found together with supporting cells in niches that controlled
the migration and diﬀerentiation of residing c-Kit+ cells [66].
However, other research groups reported that c-Kit+ cells in
adults did not become cardiomyocytes [85, 86], or that they
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became cardiomyocytes through cell fusion with very low
frequency [87], or that c-Kit+ cells could indeed generate
new cardiomyocytes during ageing and after injury, but in
extremely small quantities [88]. While this generated a
debate regarding the reliability and sensitivity of the reporter
mouse models [89, 90], it was demonstrated that an endothe-
lial population of cells in mouse hearts expressed c-Kit,
inconsistent with its role as a marker of uncommitted cells
[91]. This result supported the ﬁnding that c-Kit+ cells are
endothelial cells that are very infrequently capable of dedif-
ferentiating to cardiac stem cells [88, 91]. More recent lineage
tracing experiments conﬁrmed a small subset of cardiomyo-
cytes (∼0.03%) expressing c-Kit in the adult heart, in addition
to more abundant c-Kit+ cardiac endothelial fates [92]. This
study and others cautioned that lineage tracing is based on a
binary readout potentially overestimating contributions from
transient or low expression, as actual cardiac c-Kit expression
levels in cardiac resident cell populations isolated from adult
heart may be low. On the other hand, underestimating fac-
tors in c-Kit+ cell genetic fate-mapping studies may include
ineﬃcient Cre recombinase activity in cardiac stem cells
and deleterious consequences of c-Kit haploinsuﬃciency
resulting from genetic manipulation of the endogenous c-
Kit gene locus. These technical limitations have contributed
to the ongoing debate on rare adult stem cell populations,
which conﬁrmed the low abundance of cardiac stem cells
among the c-Kit+ cardiac cells and their very low levels of
c-Kit expression [93]. Nevertheless, c-Kit+ identiﬁes cardio-
vascular progenitors during development capable of diﬀeren-
tiating into the major cardiac lineages until at least the
neonatal stage in mammals, so an important question is
how their cardiac myogenic capacity is largely lost in the
adult [85, 94].
6.2. Epicardial Progenitors. During development, epicardium-
derived cells are known for their capability of undergoing
epithelial-to-mesenchymal transition (EMT), invading the
heart and diﬀerentiating into other cells, such as the cardiac
ﬁbroblasts [27]. A subset of Wilm’s tumour 1 Wt1(+) mouse
epicardial cells was reported to diﬀerentiate into cardiomyo-
cytes and integrate into the myocardium [97]. Furthermore, a
population of multipotent Tbx18-expressing proepicardial
progenitors was reported to diﬀerentiate into cardiomyo-
cytes, cardiac ﬁbroblasts, and coronary smooth muscle cells
[29]. These genetic lineage tracing studies relied on the epi-
cardial speciﬁcity of these markers during development,
and their ﬁndings were complicated by reports already
detecting these markers in the myocardium [98, 99]. In adult
mice, epicardium-derived progenitors residing in the epicar-
dium and subepicardium were proposed to be resident adult
cardiac stem cells. Stimulating the reexpression of the embry-
onic epicardial marker Wt1 in these cells by priming with
thymosin β4 peptide was reported to enhance their response
to subsequent injury and promote diﬀerentiation to cardio-
myocytes [65]. However, this reprogramming of epicardial
to cardiomyocytes was not observed when thymosin β4
treatment was administered after myocardial injury, when
this was tested as a treatment model [100]. The adult epicar-
dium remains a niche for progenitors that undergo EMT
upon myocardial infarction and migrate to the subepicar-
dium, where they diﬀerentiate into myoﬁbroblasts and
smooth muscle cells [101].
Table 1: Cardiac progenitor cells and their activity in the heart.
Cardiac resident progenitor type Characteristics Cardiac cell fate contribution References
Side population cells
Perivascular cells of undetermined
origin; can grow as cardiospheres
Embryonic heart: cardiomyocytes,
endothelial cells [76–78]
Adult: endothelial cells
ISL1+ cardiac progenitors
Major population of undiﬀerentiated
cardiac progenitors during development
Embryonic heart: cardiomyocytes
[79–81]
Adult: cardiomyocytes (rare)
c-Kit+ cells
Cardiovascular progenitors during
development, may be conﬁned to
endothelial fate or localised to niches
in adult
Embryonic heart: endothelial cells,
cardiomyocytes
[66, 82–94]
Adult: endothelial cells, cardiomyocytes
(rare)
Sca-1+ cells
Heart resident endothelial cells
sharing characteristics with
mesenchymal cells and side
population cells
Embryonic heart: mesenchymal,
endothelial, other
[81, 95, 96]
Adult: cardiomyocytes
(low-level replacement)
Epicardial progenitors
Capable of epithelial-to-mesenchymal
transition, multipotent progenitor
potential during development,
may be reinducible in adult
Embryonic heart: cardiomyocytes,
cardiac ﬁbroblasts, coronary
smooth muscle cells
[27, 29, 65, 97–101]
Adult: myoﬁbroblasts and
smooth muscle cells, cardiomyocytes
upon induction
Mesenchymal/stromal cells
Expressing MSC/stromal cell markers,
restricted multipotency compared
to other MSC
Adult heart: mainly cardiac
stromal/ﬁbroblast cells, limited
cardiomyocyte potential
[4, 64, 102–105]
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6.3. Cardiac Mesenchymal Cells. MSCs are adult stem cells
that can be isolated from many tissues and on this basis
may be resident in the heart [102]. However, cardiac MSCs
are not unambiguously distinguishable by speciﬁc markers
or morphology, so they have been deﬁned by their diﬀerences
from other cells or grouped with related cell types based on
shared markers [4, 64]. Furthermore, MSCs are deﬁned by
self-renewal and multipotency criteria following in vitro
tissue culture, while their primary in situ properties in many
organs are still under debate [103]. Adult human heart peri-
cytes puriﬁed from myocardium express MSC/stromal cell
markers, but their multipotency seems restricted [104].
Cardiomyocyte diﬀerentiation potential was reported to be
limited in cardiac mesenchymal cells, whether these had been
derived from myocardium or from subpericardium origins
[101, 104]. In a myocardial infarction model, these cells con-
tributed paracrine beneﬁts but diﬀerentiated into mesenchy-
mal cells, not cardiomyocyte or endothelial fates [101]. Adult
cardiac-resident MSC-like stem cells with a proepicardial
origin were described as colony-forming units-ﬁbroblasts
(CFU-Fs), which expressed platelet-derived growth factor
receptor alpha (Pdgfrα) and Sca1 [105]. These can give rise
to many cell fates but mainly cardiac stromal/ﬁbroblast cells.
The adult cardiac niche contains quiescent stem cells and
progenitors; some of which can reactivate in response to
injury, but current evidence suggests that these cells generate
primarily noncardiomyocyte cell fates or contribute to the
low rate of cardiomyocyte turnover. Adult heart progenitors
that can diﬀerentiate into other cell types such as endothelial
cells are regarded as beneﬁcial for tissue maintenance and
regeneration through their prosurvival and angiogenic func-
tions [79]. In strategies aiming to repopulate the heart, exog-
enous stem cells such as MSC and reprogrammed cells have
received considerable attention as an accessible and more
abundant source of stem cells.
7. Reprogrammed Cardiomyocytes: Recreating
Heart Developmental Potential
7.1. Cardiomyocytes from Pluripotent Stem Cells. Among the
cell replacement approaches towards cardiac regeneration is
the use of cardiomyocytes obtained by in vitro derivation
from embryonic stem (ES) or induced pluripotent stem
(iPS) cells [106]. Similar to development, a pluripotent stem
cell in a dish diﬀerentiates through the stages of mesoderm,
cardiac mesoderm, and then cardiac progenitor before ﬁnally
giving rise to a cardiomyocyte (Figure 4), with markers
allowing identiﬁcation of each diﬀerentiation stage [107].
ES and iPS cells begin to diﬀerentiate in culture by form-
ing embryoid bodies [108, 109] when LIF is removed from
the culture medium [110, 111]. The diﬀerentiation process is
directed by the expression of transcription factors, recapitu-
lating in vivo developmental stages of diﬀerentiation [110]
(Figure 2). A cardiomyocyte-like fate also occurs directly in
diﬀerentiation medium containing fetal calf serum, nones-
sential amino acids, and beta-mercaptoethanol [108, 112].
One of the issues of producing cardiomyocytes from
ﬁbroblast-derived iPS cells for cell therapeutic use is the het-
erogeneity of lineages, in which the cells will diﬀerentiate,
resulting in a variety of cells aside from cardiomyocytes and
raising tumourigenicity concerns. Inhibition or activation
of speciﬁc signalling pathways, such as treatment with glyco-
gen synthase kinase 3 inhibitors and then Wnt signalling
inhibitors [113] or optimising the levels of the signalling
molecule BMP4, key players in the speciﬁcation of cardiac
mesoderm, improved the eﬃciency of cardiomyocyte induc-
tion from iPS cells [28, 114]. Another issue is that cardiac
lineage cells mature during the diﬀerentiation process
in vivo while their beating frequency and sarcomere organi-
sation increases. However, cardiomyocyte cultures obtained
from ES or iPS cells consist mostly of immature cells with
varying levels of sarcomeric organisation and inconsistent
spontaneous contraction [115, 116]. Coculturing of cardio-
myocytes diﬀerentiated from ES cells with endothelial cells
was reported to improve their maturity and upregulate sev-
eral microRNAs, which when transfected could replicate
the eﬀect [117]. This shows that developmental microenvi-
ronments can assist in directing pluripotent stem cells to
form cardiac progenitors and cardiomyocytes in vivo, as well
as in vitro.
7.2. Cardiomyocytes Transdiﬀerentiated from Somatic Cells.
Adult cardiomyocytes can also be obtained by derivation of
other somatic cells, such as ﬁbroblasts [75, 106]. Cell repro-
gramming combines a dediﬀerentiation of ﬁbroblasts to
induced pluripotent stem (iPS) cells with directed diﬀerenti-
ation to cardiomyocytes. Transdiﬀerentiation is a technique
in which diﬀerentiated cells are reprogrammed to diﬀerent
Pluripotent
cells
NANOG
OCT4
SOX2
Mesoderm Immature
cardiomyocyte
Cardiac
progenitor
NKX2.5
GATA4
HAND1/2
MEF2C
Cardiogenic
mesoderm
Cardiomyocyte
cTnT
MHC
훼-Actinin
cTnT
MHC
훼-Actinin
MESP1
ISL1
FLK-1
Brachyury
Figure 4: Diagram illustrating diﬀerentiation of pluripotent cells to cardiomyocytes. Markers for identiﬁcation are shown for each step (red).
ES or iPS cells diﬀerentiate towards mesoderm and cardiac mesoderm through cardiac progenitors and become mature, spontaneously
contracting cardiomyocytes.
7Stem Cells International
cell lineages by direct conversion, without going through a
pluripotent stage. This has permitted the production of,
for example, neurons [118], cardiomyocytes [119], or
endothelial cells [120]. A clinical advantage of transdiﬀer-
entiation of somatic cells is that they could be taken from
the patient, thus reducing the danger of rejection, although
such treatment may not be cost-eﬀective and there is some
debate regarding the immunogenicity of reprogrammed
cells [121, 122].
It has been shown that transdiﬀerentiation reprogram-
ming occurs without passing through an ISL1+ cardiac pro-
genitor cell stage [119]. These cells show activation of genes
that are speciﬁc for cardiomyocytes, such as ryanodine
receptor 2 (Ryr2), connexin43 (Gja1), cTnT, and α-MHC
[119]. Three cardiac development transcription factors,
Gata4, Mef2c, and Tbx5, are suﬃcient for cardiomyocyte
induction in vitro and were also used to reprogramme car-
diac ﬁbroblasts to cardiomyocytes in mice in vivo after myo-
cardial infarction, reducing scar tissue [123]. Fibroblast
conversion to cardiomyocytes could be increased several-
fold by adding Hand2 to the transcription factor cocktail
[124] or by enhancing Mef2c expression relative to Gata4
and Tbx5 [125]. Through further reﬁnement, cardiomyocyte
reprogramming was achieved to speciﬁc cardiac cells such as
Purkinje [126] or pacemaker cells [127]. An alternative
transdiﬀerentiation protocol used three iPS factors, Oct4,
Klf4, and Sox2, to initiate reprogramming and then direct
cardiomyogenesis by adding BMP4 and inhibiting Janus
kinase (JAK1) [128, 129].
8. Stem Cell Engraftment in the Cardiac Niche:
Stem Cell Therapies Needing
Microenvironments
The use of exogenous allogeneic stem cell injection strategies
has focused on various populations: bone marrow-derived
cells including MSCs, progenitor cell populations, pluripo-
tent cells, and in vitro diﬀerentiated cells. Early reports sug-
gested that injected stem cells were not detectably retained
inside cardiac niches, but that positive eﬀects were never-
theless observed as a result of paracrine signalling by these
cells. A meta-analysis of stem cell therapy in the mouse
model demonstrated a signiﬁcant improvement in left ven-
tricular ejection fraction [130]. The ﬁrst reported animal
studies detected engrafted cells [131, 132]; however, very
low engraftment rates following intramyocardial cell injec-
tion are common. Myocardial engraftment in the rat model
was improved using a prosurvival cocktail with Matrigel
[133], suggesting that the allogeneic stem cell microenviron-
ment can be modulated.
A large number of clinical trials have since demonstrated
a good safety record for injecting stem cells into patients after
myocardial infarction. Comprehensive surveys of these trials
concluded an overall modest eﬃcacy in improving cardiac
function, indicating considerable variance and discrepancy
with animal studies, while the long-term beneﬁts remained
uncertain [134–138]. For instance, of a dozen studies using
injected bone marrow mononuclear cells, three noted an
improved left ventricular ejection fraction, whereas other
studies did not record diﬀerences in the patients’ cardiac
parameters, and the optimal timing of these injections after
cardiac injury also remained unclear [135]. The much larger
BAMI randomised controlled trial may be more conclusive
on bone marrow mononuclear cells [134]. On the other
hand, MSCs are immune-privileged, permitting the use of
allogeneic transplants, and they are also a better charac-
terised homogeneous population [106]. Smaller studies eval-
uating allogeneic bone marrow MSC injections were
generally encouraging [139–141]. Overall, these and other
studies indicate that the beneﬁts of cardiac cell therapy may
depend on more puriﬁed cell populations or better repro-
grammed cells, while there is no consensus regarding the best
cell type materials, which are still evolving [134].
In addition, cardiac stem cell therapies have much to gain
from improved cell engraftment. Cell retention, long-term
engraftment, and cell survival have been ongoing issues, with
an estimated 1% of donor cells surviving after 4 weeks. Low
engraftment is due to initial washout and thereafter the hos-
tile inﬂammatory environment of the injured tissue, immune
rejection, or the lack of mechanical resistance of the donor
cells [134]. It is also possible that these stem cells undergo
epigenetic changes in culture [142, 143]. Strategies towards
enhancing cell survival by preconditioning the cells for the
microenvironment of the transplantation site have been
encouraging, as well as modulation of the microenvironment
at the injured cardiac site [133, 134]. This shows that further
investigation of potential adult cardiac niches and a better
understanding of the processes by which developmental pro-
genitors are supported by their cardiac microenvironment
could lead to more eﬀective cardiac stem cell therapies.
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